Market
Story
FDA to Phase Out Phenylephrine from Cold Medicines Like Sudafed, Dayquil Due to Ineffectiveness
Dec 23, 2024, 04:53 PM
The U.S. Food and Drug Administration (FDA) has announced plans to phase out phenylephrine, a key ingredient found in many over-the-counter cold and allergy medications like Sudafed and Dayquil, due to its ineffectiveness in relieving nasal congestion. Phenylephrine, which accounts for approximately $1.8 billion in annual U.S. sales, has been questioned by experts for its efficacy. The FDA's decision follows a unanimous vote by federal advisers last year, who determined that oral phenylephrine does not outperform a placebo in clearing nasal passageways. The move is expected to lead to the reformulation or removal of products containing phenylephrine. Consumers may need to turn to alternatives such as pseudoephedrine, which is available behind pharmacy counters, or use nasal sprays and solutions like saline drops and nasal steroids for relief.
View original story
Similar markets
Other • 25%
Unauthorized flavors • 25%
Misleading health claims • 25%
Youth targeting • 25%
No significant change • 25%
Decreased trust in Alcon • 25%
Switch to alternative brands • 25%
Increased demand for safer packaging • 25%
Other • 25%
Lack of awareness • 25%
Side effects • 25%
Cost of medication • 25%
Waning vaccine protection • 25%
Other • 25%
Vaccine hesitancy • 25%
Lack of access to healthcare • 25%
Manufacturing issues • 25%
Supply chain disruptions • 25%
Increased demand • 25%
Regulatory changes • 25%
No further action • 25%
Temporary production halt • 25%
Fine imposed • 25%
Mandatory product reformulation • 25%
Less supportive of a ban • 25%
More supportive of a ban • 25%
Other opinion shift • 25%
No significant change • 25%
ZYN • 25%
Nicotine patches • 25%
Nicotine gum • 25%
Other • 25%
Increased demand for locally sourced products • 25%
No significant change • 25%
Increased demand for BPA-free products • 25%
Increased demand for organic products • 25%
Other • 25%
Rybelsus • 25%
Wegovy • 25%
Ozempic • 25%